Halozyme Therapeutics Stock News

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Halozyme's Q3 2023 earnings showed robust performance, with a 41% YoY increase in product sales and a 15% YoY growth in royalty revenue. The company's strategic moves, including a $250M share repurcha

Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to

In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).

Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and in

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.74 per share a year ago.

SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, Nove

The quest to uncover the next big success story is an ongoing pursuit for investors. Three companies are captivating exemplars of success for those seeking to turn a modest investment into a financial